Release Date: November 07, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: What level of detail should we expect in the topline readout of the Caliber study in progressive MS? Will it include subpopulation data? A: Dr. Daniel Fitt, CEO: We plan to release detailed data on both the general and sub forms tested during the study, similar to the interim analysis. This will include clinical endpoints like confirmed disability worsening, biomarkers such as NFL and GFA, and brain atrophy data. The data will be comprehensive and is expected in April next year.
Q: When might we expect data from the ongoing post-COVID investigator-led trial in Germany, and how might it relate to the Ensure trials? A: Dr. Daniel Fitt, CEO: As this is an investigator-sponsored trial, we can't provide guidance on recruitment speed. However, the role of fatigue is crucial in MS, and the overlap with EBV in both MS and post-COVID syndrome is significant. We aim to learn from this study to enhance treatment options. There is no predefined subanalysis for post-COVID syndrome in Ensure or Caliber trials, but we may extract relevant data later.
Q: What are your expectations for the hazard ratio for disability worsening in the Caliber study, and is there a potential for an accelerated approval path in PMS? A: Dr. Daniel Fitt, CEO: There is no predefined bar for the hazard ratio, but a 20% benefit would be a significant win. Regarding accelerated approval, it depends on the data and its distribution. If the data is strong, especially in nonactive secondary progressive patients, it could lead to discussions with the FDA about expedited approval.
Q: Can you discuss the unmet need in progressive MS and the potential impact of VLU calcium? A: Jason Tardio, President and COO: There is a significant unmet need, especially in nonactive secondary progressive MS, where no treatments are approved. VLU calcium's dual mechanism offers neuroprotective benefits without immunosuppression, potentially making it a gold standard in progressive MS treatment.
Q: Is Immunic in negotiations with big pharmaceutical companies for partnerships or nondilutive cash raises? A: Jason Tardio, President and COO: There is significant interest in VLU calcium from companies with interests in MS and neuroscience. While I can't provide specifics, discussions are ongoing, and interest has increased due to recent market dynamics, including BTK inhibitor failures.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.